Interventional device developer Cook is readying a U.S. clinical trial of its drug-coated stent for use in a peripheral artery. The study will examine whether drug-coated stents can yield benefits in treating peripheral vascular disease similar to those produced in treating coronary artery disease, according to the Bloomington, IN-based vendor.
Called DESTINY (Drug-Eluting Stent in the SFA/Fempop Artery), the trial will investigate the use of Cook's Zilver PTX paclitaxel-eluting stent in the above-the-knee femoropopliteal artery. The trial will be conducted initially at 10 U.S. medical facilities, with an enrollment of 60 patients.
An expanded trial will be likely, pending further Food and Drug Administration (FDA) review, Cook said. The company expects to begin patient enrollment in September.
By AuntMinnie.com staff writersJuly 28, 2004
Related Reading
Cook gets clearance for new stent, January 20, 2004
Cook to begin testing endovascular TAA graft, December 11, 2003
Cook signs three-year deal with MedAssets, August 19, 2003
Cook taps McIntosh for medical officer role, April 28, 2003
Cook signs deal with HealthTrust Purchasing, March 11, 2003
Copyright © 2004 AuntMinnie.com
